VELDONA formulation showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period.
By upregulation of immunomodulatory, Ainos' VELDONA formulation demonstrates efficacy against new variant virus based on clinical symptoms and lung inflammation.
SAN DIEGO, CA / ACCESSWIRE / September 30, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the results from its antiviral efficacy study in hamsters against the Omicron variant of SARS-CoV-2 (the "Study"). The Company's results showed that its low-dose oral interferon alpha ("IFN-") formulation, VELDONA, had a therapeutic effect on lungs infected with the SARS-CoV-2 (the "Omicron variant") virus by regulating the immune response, thereby expediting recovery of infected animals. The Company has submitted the application documents for U.S. FDA Phase 2 clinical trials for evaluating the efficacy of VELDONA in patients with mild COVID-19. Further information regarding the Study can be found on Ainos' website (link).
The Study evaluated the effectiveness of VELDONA over a sixteen-day course (five-day pre-treatment, one-day during viral infection and ten-day treatment after infection) of Omicron-variant-infected hamsters. Compared with hamsters in the placebo group receiving solution without VELDONA (the "Placebo Group"), the hamsters in the group receiving solution with VELDONA (the "VELDONA Group") demonstrated resistance to body weight loss immediately after infection, then showed a better recovery trend in the following three days. The body weights of the hamsters in the VELDONA Group remained more stable than those of the hamsters in the Placebo Group during the treatment period.
Mean Body Weight Throughout the Treatment Period
Percentage of Body Weight Change
For pathological indicators, on the tenth day, no hamsters in the VELDONA Group showed mixed-cellular inflammation, peribronchial infiltration, and perivascular infiltration, compared to 50% of hamsters in the Placebo Group. Hamsters in the VELDONA Group in general showed promising results in treating indicators of new variant virus infection.
Lung Pathology Report
Mixed cellular inflammation, peribronchial infiltration, and perivascular infiltration.
Chun-Hsien Tsai, Ainos' Chairman of the Board, President, and Chief Executive Officer, commented, "Ainos has conducted three preclinical animal studies since March 2022 in our efforts to validate the effectiveness of our low-dose oral interferon to protect against symptoms associated with COVID-19 (Delta and Omicron variants). The studies have yielded consistent results, demonstrating VELDONA's efficacy in inducing systemic immunomodulatory to fight against SARS-COV-2. The results of the two-week study also showed that VELDONA is well-tolerated and safe in hamsters. In addition, this new study exhibited a preventative and therapeutic effect against new variant virus. Ainos believe that these results, in combination with the results of our previous two Phase 2 studies of VELDONA on prevention and treatment of influenza, demonstrate that VELDONA may become an important solution for the treatment of COVID-19 and other viral infections in the future. Furthermore, we would like to thank the Emerging Infectious Disease Core Facility Platform of the National Defense Medical Center in Taiwan for the support and professional technical services they provided for the Study."
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. (f/k/a Amarillo Biosciences, Inc.) is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. In addition to its proprietary therapeutics using low-dose non-injectable interferon, Ainos is committed to developing a comprehensive healthcare business portfolio encompassing medical devices and consumer healthcare products. While prioritizing the commercialization of medical devices as part of its diversification strategy, Ainos has also expanded its product portfolio to include Volatile Organic Compounds (VOC) and COVID-19 POCTs. Leveraging its patents related to VOC technologies and COVID-19 POCT products, the Company seeks to expedite the commercialization of its medical device pipeline, beginning with Ainos-branded COVID-19 POCT product candidates.
Forward-Looking Statements
This press release contains "forward-looking statements" about Ainos within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the planned drug treatments announced in this press release; the Company's dependence on revenues from the sale of COVID-19 test kits; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; and the Company's success in managing the growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' most recent Annual Report on Form 10-K/A and other reports filed with the U.S. Securities and Exchange Commission, many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's Form 10-K/A, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Investor Relations Contact
ICR, LLCRobin YangTel: +1 646-224-6971Email: Ainos.IR@icrinc.com
SOURCE: Ainos, Inc.
View source version on accesswire.com:https://www.accesswire.com/718287/Ainos-Announces-Positive-Results-from-Additional-Preclinical-Study-of-Its-Low-dose-Oral-Interferon-Formulation-Against-New-Variant-Virus--Omicron
- Preventive or Preventative: Is There a Difference? - Merriam-Webster - January 21st, 2023
- Nurses: The Frontlines of Preventative Care - Bradley University Online - November 24th, 2022
- Functional Medicine of Idaho | Preventative Root Cause Medicine - October 29th, 2022
- This Indigenous Scientist Helped Save Lives as Covid Devastated the Navajo Nation - Scientific American - October 13th, 2022
- As governor calls for better mental health services, Healthy Wyoming says Medicaid expansion needed - Oil City News - October 13th, 2022
- Clinisys formed to help companies manage 'revolution' of lab science - OutSourcing-Pharma.com - October 13th, 2022
- North Korea tells officials that 350,000 people died of diseases this year - Radio Free Asia - October 4th, 2022
- Episode 45 - Preventative Medicine: the Mediterranean Diet and the ... - September 25th, 2022
- Women's health got worse in 2021, global survey finds - WXOW.com - September 25th, 2022
- Wolf Creek PCN expands programming geared to health improvement - Lacombe Express - September 25th, 2022
- 1 in 10 Adults and 1 in 5 Teens Have Symptoms of Depression, What We Know - Healthline - September 25th, 2022
- Three tips to keep youth athletes in top nutritional shape this school year - The Philadelphia Inquirer - September 25th, 2022
- A blood test that detects cancer without symptoms could be a game changer for Louisiana - NOLA.com - September 25th, 2022
- Eric Idle on Surviving Pancreatic Cancer - TIME - September 25th, 2022
- Attacks on hospitals and healthcare in Ukraine: Joint Submission to the United Nations Independent International Commission of Inquiry on Ukraine,... - September 25th, 2022
- Spending on Food and lifestyle for preventive wellness is better than spending on medicines and treatment - The Financial Express - September 25th, 2022
- Exercise is Preventative Medicine - myBurbank.com - September 16th, 2022
- Best preventative medicine, health screening and anti-ageing clinics for HNWs in 2022 - Spear's WMS - September 16th, 2022
- The high hospital bills we make victims of rape and sexual violence pay - Vox.com - September 16th, 2022
- Press Release: CHMP recommends approval of Beyfortus (nirsevimab) for prevention of RSV disease in infants - StreetInsider.com - September 16th, 2022
- Why Now is the Time to Double Down on Virtual Care - HIT Consultant - September 16th, 2022
- Pickleball injuries are on the rise: 5 preventive tips to keep you on the court - The Manual - September 16th, 2022
- Opinion: From the Great War to the pandemic, doctors and nurses have always carried a heavy burden - The Globe and Mail - September 16th, 2022
- Can Sustainable Initiatives Benefit Your Team's Mental Health As Well As The Environment? - MinuteHack - September 16th, 2022
- Management of Chronic Migraine in Children and Adolescents | PHMT - Dove Medical Press - September 16th, 2022
- Workshop on promotion of physical activity in pregnancy | JMDH - Dove Medical Press - September 16th, 2022
- Men at The Emeline: how preventative medical care can help keep you on track - Australian Jewish News - August 30th, 2022
- Study: PCPs Need 26.7 Hours Per Day to Provide Recommended Care - Healthcare Innovation - August 30th, 2022
- New Guidelines Target Preventing Obesity In Midlife Women, But The Conclusion Is Somewhat Controversial - Suggest - August 30th, 2022
- Colleges need to prepare for monkeypox to spread among students, infectious disease experts say - PhillyVoice.com - August 30th, 2022
- BHERC Presents Its First Health Matters Film Screening and Panel Focused on Mental Health During The 28th Annual African American Film Marketplace and... - August 30th, 2022
- The Antitumor Effects of Quercetin - The Epoch Times - August 30th, 2022
- Why 4mg of folic acid will dramatically reduce the risk of birth defects during pregnancy - iNews - August 22nd, 2022
- Cure Is An Absolute, But Prevention Is The Ideal Vasanthi Ramachandran - CodeBlue - August 22nd, 2022
- GET PREPPED FOR A HEALTHY AND PRODUCTIVE SCHOOL YEAR - PR Newswire - August 22nd, 2022
- Researchers examine link between pesticides and thyroid cancer risk in Central California area - EurekAlert - August 22nd, 2022
- 5 Ways Your Body Is Telling You That You Need More Potassium, According to a Cardiologist and a Dietitian - Well+Good - August 22nd, 2022
- Restore Hyper Wellness Announces First Half of 2022 Performance Results with Over $60M in System-Wide Sales & Official Announcement of its Medical... - August 22nd, 2022
- Quest Diagnostics Aims to Close Gaps in Maternal Healthcare with New Obstetrics Test Panel that Includes Hepatitis C Screening - PR Newswire - August 22nd, 2022
- Flu Viral: Here Are The Most Common Queries Answered - NDTV - August 22nd, 2022
- Letters to the Editor, Aug. 19, 2022 - Toronto Sun - August 22nd, 2022
- Gambia: How Covid-19 vaccine contributes to the immunization of the most vulnerable - - Voice Gambia Newspaper - August 22nd, 2022
- The Effect of Maintenance Treatment with Erdosteine on Exacerbation Tr | COPD - Dove Medical Press - August 22nd, 2022
- Diagnostic Robotics has AI catching health problems before they take you to the ER - TechCrunch - August 14th, 2022
- Roches Xofluza issued FDA approval to treat influenza in children aged five years and older - PMLiVE - August 14th, 2022
- Ananta Medicare Provides Preventative Health Solutions to the World - PR Newswire - July 19th, 2022
- 5 "Health Tips" That are Terrible for Over 50s Eat This Not That - Eat This, Not That - July 19th, 2022
- 'Death Cap' Mushrooms Pose Threat to Dogs - University of Wisconsin School of Veterinary Medicine - University of Wisconsin School of Veterinary... - July 19th, 2022
- What Medicaid expansion means for new moms in Virginia - CBS 6 News Richmond WTVR - July 11th, 2022
- Healthcare for the Busy Bee - Flathead Beacon - July 11th, 2022
- The COVID BA.4 and BA.5 subvariants are highly transmissible. Here's what else people in CT need to know. - CT Insider - July 11th, 2022
- NHS to test using drones to fly chemotherapy drugs to Isle of Wight - The Guardian - July 11th, 2022
- The Role of Smoking and Body Mass Index in Mortality Risk Assessment for Geriatric Hip Fracture Patients - Cureus - July 11th, 2022
- Family Health Care Atlanta | Primary & Preventative Medicine - July 3rd, 2022
- Preventative medicine in Rochester Hills MI - July 3rd, 2022
- Joan Merriam: Prevention is the best medicine - The Union - June 22nd, 2022
- RIVERVIEW PRIMARY CARE PROVIDERS AVAILABLE TO OVERSEE YOUR HEALTH NEEDS - kroxam.com - June 22nd, 2022
- Prevention is the best medicine | Caseys Corner - Oroville Mercury-Register - June 22nd, 2022
- With Father's Day in mind, Mayo Clinic doctors remind men to be mindful of their health - WQOW TV News 18 - June 22nd, 2022
- Vilcek-Gold Award for Humanism in Healthcare will be presented this fall to Health Equity Leader Dr. Mona Fouad - City-sentinel - June 13th, 2022
- Margolius named Cleveland director of public health - Cleveland Jewish News - June 13th, 2022
- Three things to know about COVID-19 at this time: Dr. Robert A. Salata - cleveland.com - June 13th, 2022
- Remission seen in every rectal cancer patient in small study of drug - The Hill - June 13th, 2022
- University of Vermont: Advancing healthcare through impactful medicine - Study International News - June 13th, 2022
- On Three Different Continents, Rural Health Strains under the Weight of the Coronavirus - Scientific American - June 13th, 2022
- Do You Suffer from Knee Pain Due to Inflammation or Arthritis? Taking More Walks Will Help, a New Study Shows - Yahoo Life - June 13th, 2022
- Benign Breast Lumps | Health, Medicine and Fitness | siouxcityjournal.com - Sioux City Journal - June 13th, 2022
- 'We are definitely missing cases:' Just a fraction of COVID-19 cases reported in Washington - KING5.com - June 13th, 2022
- Flea-borne typhus outbreak puts three Aucklanders in hospital - Stuff - June 13th, 2022
- Promoters of Preventive Health A Key Role in Nursing - wknd. - May 15th, 2022
- What we know (and don't know) about North Korea's Covid outbreak - WREX.com - May 15th, 2022
- Metabolic Health and Skin Care: What to Know - WWD - May 15th, 2022
- VERIFY Fact Sheet: COVID-19 treatments - VERIFYThis.com - May 15th, 2022
- Twitter: AI applications in healthcare and more - Pharmaceutical Technology - May 15th, 2022
- How Jefferson Health is harnessing philanthropy to address health disparities - Becker's Hospital Review - May 15th, 2022
- Digital Health Companies Bring Paradigm Change Across the Health... - Healthcare Tech Outlook - May 15th, 2022
- We all have a heros journey and our job is to triumph over our tragedies - Kitimat Northern Sentinel - May 15th, 2022
- Doctor Reveals How Woke Activists Have Infiltrated Medicine - Daily Signal - May 15th, 2022
- Study: Serious COVID-19 Outcomes Are More Likely Among Unvaccinated With Heart Issues - Pharmacy Times - May 15th, 2022
- What are the Key Opportunities on Offer for Self-care Medical Device Manufactures Exclusive Study - PharmiWeb.com - May 15th, 2022